2012 Kern Lipid Conference

描述(由申请者提供)：2012年克恩脂肪会议将探索脂质组学、系统生物学和心脏代谢风险决定因素之间的接口，以便在不同学科工作的研究科学家和受训人员将聚集在一个真正独特的大学论坛上，讨论与关键健康优先事项相关的研究。《克恩》 会议传统上侧重于脂代谢与复杂的心脏代谢疾病之间的关系，如血脂异常、动脉粥样硬化和糖尿病，2012年的会议也不会例外。会议计划旨在涵盖系统生物学方法在描绘复杂心脏代谢性疾病原因方面的新作用的新信息。在过去的几年里，人们对系统生物学方法对多组分生物过程的兴趣重新燃起，例如导致2型糖尿病、血脂异常和动脉粥样硬化的病理学。这在一定程度上是由于技术的发展，如表达阵列和下一代测序，这些发展导致了在全球一级询问生物系统的能力，并为实施治疗复杂疾病的个性化医学方法打开了大门。其次，正在开发新的计算和数学方法，如网络建模，以从高通量和其他数据中提取生物信息。最后，人们越来越认识到，仅靠简化论的方法不会让我们完全解决常见形式的心脏病和糖尿病中的遗传和环境相互作用等问题。董事会已选定A·杰克·路易斯博士、玛格丽特·施瓦茨博士和罗杰·牛顿博士担任会议的联席主席。这三人都是克恩董事会的成员。Lusis博士是加州大学洛杉矶分校的人类遗传学教授。他的研究重点是代谢和心血管疾病的遗传学。施瓦茨博士是安进公司动脉粥样硬化的主管。她对脂代谢和心血管疾病感兴趣。罗杰·牛顿博士是密歇根州普利茅斯Esperion治疗公司的总裁。他的兴趣是药理学和心血管疾病。公共卫生相关性：本次会议的目标是为与会者提供一个机会，了解脂类组学和系统生物学方法的最新进展，并听取和讨论关于它们作为研究心脏代谢性疾病工具的相关性的陈述。

DESCRIPTION (provided by applicant): The 2012 Kern Lipid Conference will explore the interface between lipidomics, systems biology and factors determining cardiometabolic risk so that research scientists and trainees working in diverse disciplines will be brought together in a truly unique and collegiate forum to address research relevant to vital health priorities. The Kern Conference has traditionally focused on the relationships between lipid metabolism and complex cardiometabolic diseases such as dyslipidemia, atherosclerosis and diabetes, and the 2012 meeting will be no exception. The meeting program is designed to cover new information on the emerging role of systems biology approaches for delineating the causes of complex cardiometabolic diseases. The last several years have witnessed a revival in interest in systems biology approaches to multicomponent, biologic processes such as the pathologies leading to type 2 diabetes, dyslipidemias and atherosclerosis. This is, in part, due to technical developments, such as expression arrays and next generation sequencing, that have resulted in the ability to interrogate biologic systems at a global level and open the door for implementing personalized medicine approaches for the treatment of complex disease. Second, new computational and mathematical approaches, such as network modeling, are being developed to extract biologic information from high throughput and other data. And, finally, there is a growing realization that reductionist approaches will not, alone, allow us to fully address problems such as the genetic and environmental interaction in common forms of heart disease and diabetes. The Board of Directors has selected Drs. A. Jake Lusis, Margrit Schwarz and Roger Newton to be the Co- Chairs of the meeting. All three are members of the Kern Board of Directors. Dr. Lusis is Professor of Human Genetics at the University of California, Los Angeles. His research has focused on the genetics of metabolic and cardiovascular diseases. Dr. Schwarz is Director of Atherosclerosis, Amgen, Inc. Her interests are in lipid metabolism and cardiovascular diseases. Roger Newton, Ph.D., is President of Esperion Therapeutics, Plymouth, MI. His interests are in pharmacology and cardiovascular disease. PUBLIC HEALTH RELEVANCE: The goal of this meeting is to provide attendees an opportunity to learn the latest advances in lipidomics and systems biology approaches, as well as, hear and discuss presentations on their relevance as tools for investigating cardiometabolic disease.